Key result
One year after treatment with docetaxel, doxorubicin, and cyclophosphamide, 29.1% of breast cancer patients had abnormal biomarker levels, and elevated NT-proBNP correlated with reduced left ventricular ejection fraction.
Why the study?
Does a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2, sFlt-1) detect subclinical cardiotoxicity 1 year after treatment with docetaxel, doxorubicin, and cyclophosphamide in breast cancer patients?
Cohort (n=55)
No
Does a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2, sFlt-1) detect subclinical cardiotoxicity 1 year after treatment with docetaxel, doxorubicin, and cyclophosphamide in breast cancer patients?
A diverse biomarker panel including TNF-α, galectin-3, IL-6, Troponin I, ST2, and sFlt-1 does not contribute to early detection of subclinical cardiotoxicity 1 year after anthracycline treatment, suggesting future surveillance should focus on NT-proBNP.
Answers are grounded in this paper and cite their sources.
NT-proBNP may aid post-anthracycline surveillance; leaves open whether additional biomarkers add value in prospective studies.
OBJECTIVE: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. METHODS: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. RESULTS: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = -0.564, p ≤ 0.01). CONCLUSION: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
No takes yet. Share an insight, caveat, or question.
Boxtel et al. (2015) conducted a cohort in Breast cancer (n=55). Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy vs. Normal biomarker levels was evaluated on Prevalence of abnormal biomarkers (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1). One year after treatment with docetaxel, doxorubicin, and cyclophosphamide, 29.1% of breast cancer patients had abnormal biomarker levels, and elevated NT-proBNP correlated with reduced left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: